Beyond the genome: Regeneron’s Abecasis on scaling drug discovery with genetic data

• Genetics as a scalable drug discovery platform — Regeneron treats human genetics as a long-term platform investment, combining cloud infrastructure, automation, and external collaborations to build a large, diverse exome-plus-health-data resource with strategic value across therapeutic areas

• Raising the bar for target selection — Genetic findings must be statistically convincing, clinically meaningful, and compatible with modalities such as antibodies, siRNA, or gene editing, which makes the process highly curated rather than volume-driven...